139 related articles for article (PubMed ID: 38342656)
1. Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review.
Baun C; Naghavi-Behzad M; Hildebrandt MG; Gerke O; Thisgaard H
Semin Nucl Med; 2024 Mar; 54(2):256-269. PubMed ID: 38342656
[TBL] [Abstract][Full Text] [Related]
2. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.
Dalm SU; Sieuwerts AM; Look MP; Melis M; van Deurzen CH; Foekens JA; de Jong M; Martens JW
J Nucl Med; 2015 Oct; 56(10):1487-93. PubMed ID: 26251419
[TBL] [Abstract][Full Text] [Related]
3. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
4. Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.
Morgat C; MacGrogan G; Brouste V; Vélasco V; Sévenet N; Bonnefoi H; Fernandez P; Debled M; Hindié E
J Nucl Med; 2017 Sep; 58(9):1401-1407. PubMed ID: 28280221
[TBL] [Abstract][Full Text] [Related]
5. Theranostic Prospects of Gastrin-Releasing Peptide Receptor-Radioantagonists in Oncology.
Maina T; Nock BA; Kulkarni H; Singh A; Baum RP
PET Clin; 2017 Jul; 12(3):297-309. PubMed ID: 28576168
[TBL] [Abstract][Full Text] [Related]
6. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
8. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
[TBL] [Abstract][Full Text] [Related]
9. Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer.
Dalm SU; Schrijver WA; Sieuwerts AM; Look MP; Ziel-van der Made AC; de Weerd V; Martens JW; van Diest PJ; de Jong M; van Deurzen CH
PLoS One; 2017; 12(1):e0170536. PubMed ID: 28107508
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
Morgat C; Schollhammer R; Macgrogan G; Barthe N; Vélasco V; Vimont D; Cazeau AL; Fernandez P; Hindié E
PLoS One; 2019; 14(1):e0210905. PubMed ID: 30645633
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH
Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002
[TBL] [Abstract][Full Text] [Related]
12. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
13. From Bench to Bed: New Gastrin-Releasing Peptide Receptor-Directed Radioligands and Their Use in Prostate Cancer.
Maina T; Nock BA
PET Clin; 2017 Apr; 12(2):205-217. PubMed ID: 28267454
[TBL] [Abstract][Full Text] [Related]
14. Substitution of l-Tryptophan by
Günther T; Deiser S; Felber V; Beck R; Wester HJ
J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
[TBL] [Abstract][Full Text] [Related]
15. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
[TBL] [Abstract][Full Text] [Related]
16. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
17. The association of 18F-fluorodeoxyglucose PET/computed tomography parameters with tissue gastrin-releasing peptide receptor and integrin αvβ3 receptor levels in patients with breast cancer.
Arslan E; Aksoy T; Can Trabulus FD; Kelten Talu C; Yeni B; Çermik TF
Nucl Med Commun; 2020 Mar; 41(3):260-268. PubMed ID: 31895261
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
